

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

03 July 2024

**CRISM Therapeutics Corporation**  
**(AIM:CRTX)**

**Response to Movement in Share Price**

CRISM Therapeutics Corporation ("CRISM" or the "Company") notes the increase in the Company's share price today and confirms that it is not aware of any specific reason for the increase. The Company's share price has fallen since admission to AIM (Admission) on 31 May 2024, and today's price reversal reflects the Board's underlying view of the value of the business. The Company continues to work on its stated strategy of submitting a Clinical Trial Application in the second half of 2024 for its lead product, ChemoSeed. The Company is also at contract stage to provide services with an early stage UK SME who are seeking to utilise CRISM's drug formulation expertise. The value of that contract would be approximately £230k + VAT. A further announcement will be made in due course.

**Enquiries:**

Company	Nomad and Broker	Financial PR
<b>CRISM Therapeutics Corporation</b>	<b>S.P. Angel Corporate Finance LLP</b>	<b>Buchanan</b>
Andrew Webb, CEO Chris McConville, CSO	Richard Morrison Adam Cowl	Mark Court mark.court@buchanancomms.co.uk Jamie Hooper jamie.hooper@buchanancomms.co.uk
via Buchanan	+44 (0) 20 3470 0470	+44 (0) 20 7466 5000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

SPMSSMFIDELSEFW